Denali Therapeutics (DNLI) Research & Development (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Research & Development of $103.8 million for Q1 2026, down 10.65% year-over-year from $116.2 million in Q1 2025, and up 6.07% quarter-over-quarter from $97.9 million in Q4 2025.
Denali Therapeutics (DNLI) Research & Development (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Research & Development for 10 consecutive years, with $103.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 10.65% year-over-year to $103.8 million; the TTM figure through Mar 2026 stood at $406.4 million (changed 0.18% YoY), while the FY2025 annual figure was $418.8 million, up 5.63% from the prior year.
- Research & Development rose to $103.8 million in Q1 2026 per DNLI's latest filing, from $97.9 million in the prior quarter.
- Across five years, Research & Development topped out at $128.8 million in Q1 2023 and bottomed at $86.1 million in Q1 2022.
- Historically, Research & Development has averaged $100.1 million across 5 years, with a median of $98.2 million in 2024.
- Annual changes were most pronounced in 2023 — Research & Development jumped 49.62% — and 2024, when it decreased 16.92%.
- Denali Therapeutics' Research & Development stood at $92.1 million in 2022, then advanced by 17.04% to $107.8 million in 2023, then declined by 7.44% to $99.8 million in 2024, then slipped by 1.89% to $97.9 million in 2025, then rose by 6.07% to $103.8 million in 2026.
- Business Quant data shows DNLI's Research & Development at $103.8 million in Q1 2026, $97.9 million in Q4 2025, and $101.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 97.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.02 Mn |
| Mar 31, 2026 | 103.85 Mn |
| Dec 31, 2025 | 97.91 Mn |
| Sep 30, 2025 | 101.95 Mn |
| Jun 30, 2025 | 102.70 Mn |
| Mar 31, 2025 | 116.23 Mn |
| Dec 31, 2024 | 99.79 Mn |
| Sep 30, 2024 | 98.24 Mn |
| Jun 30, 2024 | 91.40 Mn |
| Mar 31, 2024 | 107.02 Mn |
| Dec 31, 2023 | 107.80 Mn |
| Sep 30, 2023 | 89.74 Mn |
| Jun 30, 2023 | 97.52 Mn |
| Mar 31, 2023 | 128.82 Mn |
| Dec 31, 2022 | 92.11 Mn |
| Sep 30, 2022 | 87.79 Mn |
| Jun 30, 2022 | 92.74 Mn |
| Mar 31, 2022 | 86.10 Mn |
| Dec 31, 2021 | 67.88 Mn |
| Sep 30, 2021 | 71.56 Mn |